Key Highlights

• Telix Pharmaceuticals (ASX:TLX) closed at A$14.08, up 5.71%, as the company progresses its radiopharmaceutical pipeline with multiple clinical and commercial milestones.

• Clarity Pharmaceuticals (ASX:CU6) closed at A$1.60, surging 15.94%, following its quarterly activity report for the September 2026 quarter.

• Racura Oncology (ASX:RAC) closed at A$1.48, gaining 5.71%, after reporting that it had safely treated its first patient with RC220 and osimertinib in the HARNESS-1 trial.

The S&P/ASX 200 (XJO) closed at 9,065.10 on 5 November 2026, up 2.61% or 230.60 points, while the S&P/ASX 200 Health Care index (XHJ) advanced 3.64%, adding 1,240.30 points to close at 35,329.10. Overnight Wall Street gains following the Democrats' decisive midterm election victory provided a positive global backdrop. Oncology-focused companies on the ASX were notable outperformers during the session, with Telix Pharmaceuticals Ltd (ASX:TLX), Clarity Pharmaceuticals Ltd (ASX:CU6), and Racura Oncology Ltd (ASX:RAC) each posting gains above the broader market.

Telix Pharmaceuticals — Radiopharmaceutical Pipeline Advancing

Telix Pharmaceuticals Ltd (ASX:TLX), a global biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals, closed at A$14.08 on 5 November 2026, up 5.71%. Telix has an approved diagnostic imaging product, Illuccix, which is used in prostate cancer diagnosis, and maintains a pipeline of therapeutic radiopharmaceutical candidates.

Telix released its Q3 2026 activity report in October, detailing progress across its clinical programmes and commercial operations. The company has been expanding its Manufacturing capabilities and progressing its therapeutic candidates through clinical trials. Telix earlier filed its NEURACTHEL product submission, and its pipeline spans prostate, kidney, and brain cancers as well as other indications. The company generates Revenue from commercial sales of Illuccix across multiple markets.

Clarity Pharmaceuticals — Quarterly Momentum

Clarity Pharmaceuticals Ltd (ASX:CU6), a clinical-stage radiopharmaceutical company developing next-generation copper-based theranostic products, closed at A$1.60, surging 15.94%. The company released its quarterly activity report for the September 2026 quarter, providing updates on its clinical programmes and cash position.

Clarity's platform utilises copper-64 and copper-67 isotopes for both diagnostic imaging and targeted therapy. The company's lead programmes target prostate cancer and neuroendocrine tumours, with Clinical Trials underway in multiple jurisdictions. The significant share price gain on 5 November 2026 reflected investor interest in the radiopharmaceuticals space, though no single catalyst from the Quarterly Report was identified as the primary driver.

Racura Oncology — First Patient Treated in HARNESS-1

Racura Oncology Ltd (ASX:RAC), a clinical-stage oncology company, closed at A$1.48, gaining 5.71%. The company's quarterly activities report for the September 2026 quarter highlighted a key milestone — the first patient had been safely treated with RC220 and osimertinib in the HARNESS-1 trial for patients with EGFR-mutated non-small cell lung cancer.

Racura also reported that its Phase 1 CPACS trial had expanded to South Korea to accelerate patient recruitment, and that ethics approval had been received for additional HARNESS-1 sites in New South Wales and Victoria. The company reported a cash balance of A$30.7 million at 30 September 2026, providing runway to advance its clinical programmes.

Sector Context

The radiopharmaceutical and oncology sub-sector on the ASX has attracted increasing attention from investors as global interest in targeted cancer therapies continues to grow. Telix leads the group with commercial revenues and a diversified pipeline, while Clarity and Racura represent earlier-stage opportunities with differentiated technology platforms. The sector benefits from a global shift toward precision oncology and the increasing use of radioisotope-based diagnostics and therapeutics. The XHJ's 3.64% advance on 5 November 2026 provided a supportive backdrop for oncology names.

The Takeaway

All three oncology-focused companies outperformed the broader healthcare index on 5 November 2026, with Clarity Pharmaceuticals' 15.94% gain the most notable. Telix's 5.71% advance reflects its more established position with commercial revenues, while Racura's 5.71% gain followed a clinically meaningful milestone in its HARNESS-1 trial. The oncology sub-sector continues to benefit from the global expansion of targeted cancer diagnostics and therapeutics.